Nicotinamide mononucleotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-29. Numbers and descriptions here follow the published literature rather than marketing material.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C11H15N2O8P | Pyridinium nucleotide; free acid form |
| Molar mass | 334.22 g/mol | Free acid; salt forms differ |
| Appearance | White to off-white powder | Typical reference material |
| Solubility class | Water-soluble | Hygroscopic under humid conditions |
| Common synonyms | Nicotinamide mononucleotide; NMN | Distinct from nicotinamide riboside |
Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.
NMN occurs in many living systems, including bacteria, yeast, plants, and mammals. Dietary sources are present in foods such as edamame, avocado, broccoli, and various meats, but amounts vary widely and are generally lower than those used in research settings. Laboratory production often relies on enzymatic synthesis or chemical phosphorylation of nicotinamide riboside, and commercial material is typically supplied as a white to off-white powder. Because NMN is hygroscopic and sensitive to heat, moisture, and pH extremes, its handling requires care to preserve identity and purity. Aqueous preparation should be done with attention to pH and temperature to limit hydrolysis.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
A 2025 review by the theory's originators sets it against opponent-process theories, habit theories, and theories centered on impaired prefrontal control, and addresses continuing debate over whether craving is central to addiction and whether addictive behavior is accurately described as compulsive. In contrast to ΔFosB's reward-sensitizing effect, CREB transcriptional activity decreases user's sensitivity to the rewarding effects of the substance. CREB transcription in the nucleus accumbens is implicated in psychological dependence and symptoms involving a lack of pleasure or motivation during drug withdrawal.
Scheele sourced uric acid from human calculi (such as kidney stones) and called the compound lithic acid. William Prout investigated the compound in 1818, and he used boa constrictor excrement with up to 90% ammonium acid urate. In the chapter "Nitrogen" of his memoir The Periodic Table, Primo Levi tells of his futile attempt to make alloxan for a cosmetics manufacturer who has read that it can cause permanent reddening of the lips. Levi considers the droppings of pythons as a source for uric acid for making alloxan, but he is turned down by the director of the Turin zoo because the zoo already has lucrative contracts with pharmaceutical companies, so he is obliged to use chickens as his source of uric acid. The synthesis fails, however, "and the alloxan and its resonant name remained a resonant name."
Carboxypeptidase A usually refers to the pancreatic exopeptidase that hydrolyzes peptide bonds of C-terminal residues with aromatic or aliphatic side-chains. Most scientists in the field now refer to this enzyme as CPA1, and to a related pancreatic carboxypeptidase as CPA2.
=== Digestion and excretion === The digestive system begins with the buccal mass which consists of the mouth with the beak, the pharynx, radula and salivary glands. The radula is serrated and made of chitin. Food is broken down and is forced into the esophagus by two lateral extensions of the oesophageal side walls in addition to the radula. From there it is transferred to the gastrointestinal tract, which is mostly suspended from the roof of the mantle cavity. The tract consists of a crop, where the food is stored; a stomach, where it is mixed with other gut material; a caecum where the food is separated into particles and liquids and which absorbs fats; the digestive gland, where liver cells break down and absorb the fluid and become "brown bodies"; and the intestine, where the built-up waste is turned into faecal ropes by secretions and ejected out of the funnel via the rectum. During osmoregulation, fluid is added to the pericardia of the branchial hearts. The octopus has two nephridia (equivalent to vertebrate kidneys) that are associated with the branchial hearts; these and their associated ducts connect the pericardial cavities with the mantle cavity. Each branch of the vena cava has renal appendages that pass over the thin-walled nephridium before reaching the branchial heart. Urine is created in the pericardial cavity, and is altered by excretion, of mostly ammonia, and absorption from the renal appendages, as it is passed along the associated duct and through the nephridiopore into the mantle cavity.
=== T cell epitopes === T cell epitopes are presented on the surface of an antigen-presenting cell, where they are bound to major histocompatibility complex (MHC) molecules. In humans, professional antigen-presenting cells are specialized to present MHC class II peptides, whereas most nucleated somatic cells present MHC class I peptides. T cell epitopes presented by MHC class I molecules are typically peptides between 8 and 11 amino acids in length, whereas MHC class II molecules present longer peptides, 13–17 amino acids in length, and non-classical MHC molecules also present non-peptidic epitopes such as glycolipids.
Sources: en.wikipedia.org
=== Other properties === Another important property for potential applications is the extent of phase separation, represented by the difference in polymer content in the two phases after phase separation. For most applications, phase separation in pure polymer and pure solvent would be desirable although it is practically impossible. The extent of phase separation in a given temperature interval depends on the particular polymer-solvent phase diagram. Example: From the phase diagram of polystyrene (molar mass 43,600 g/mol) in the solvent cyclohexane it follows that at a total polymer concentration of 10%, cooling from 25 to 20 °C causes phase separation into a polymer-poor phase with 1% polymer and a polymer-rich phase with 30% polymer content. Also desirable for many applications is a sharp phase transition, which is reflected by a sudden drop in transmittance. The sharpness of the phase transition is related to the extent of phase separation but additionally relies on whether all present polymer chains exhibit the same cloud point. This depends on the polymer endgroups, dispersity, or—in the case of copolymers—varying copolymer compositions. As a result of phase separation, thermoresponsive polymer systems can form well-defined self-assembled nanostructures with a number of different practical application such as in drug and gene delivery, tissue engineering, etc.
=== Examples === A RING (Really Interesting New Gene) domain binds the E2 conjugase and might be found to mediate enzymatic activity in the E2-E3 complex An F-box domain (as in the SCF complex) binds the ubiquitinated substrate. (e.g., Cdc 4, which binds the target protein Sic1; Grr1, which binds Cln). A HECT domain, which is involved in the transfer of ubiquitin from the E2 to the substrate.
On January 10, 2007, Bush launched a surge of 21,500 more troops for Iraq, as well as a job program for Iraqis, more reconstruction proposals, and $1.2 billion (equivalent to $1.9 billion in 2025) for these programs. On May 1, 2007, Bush used his second-ever veto to reject a bill setting a deadline for the withdrawal of U.S. troops, saying the debate over the conflict was "understandable" but insisting that a continued U.S. presence there was crucial. In March 2008, Bush praised the Iraqi government's "bold decision" to launch the Battle of Basra against the Mahdi Army, calling it "a defining moment in the history of a free Iraq". He said he would carefully weigh recommendations from his commanding General David Petraeus and Ambassador Ryan Crocker about how to proceed after the end of the military buildup in the summer of 2008. He also praised the Iraqis' legislative achievements, including a pension law, a revised de-Baathification law, a new budget, an amnesty law, and a provincial powers measure that, he said, set the stage for the Iraqi elections. By July 2008, American troop deaths had reached their lowest number since the war began, and due to increased stability in Iraq, Bush withdrew additional American forces. During Bush's last visit to Iraq in December 2008, Iraqi journalist Muntadhar al-Zaidi threw both of his shoes at him during an official press conference with Iraqi Prime Minister Nouri al-Maliki. Al-Zaidi yelled that the shoes were a "farewell kiss" and "for the widows and orphans and all those killed in Iraq".
=== Purifications and measurements of mass === The minimum molecular weight suggested by Mulder's analyses was roughly 9 kDa, hundreds of times larger than other molecules being studied. Hence, the chemical structure of proteins (their primary structure) was an active area of research until 1949, when Fred Sanger sequenced insulin. The (correct) theory that proteins were linear polymers of amino acids linked by peptide bonds was proposed independently and simultaneously by Franz Hofmeister and Emil Fischer at the same conference in 1902. However, some scientists were sceptical that such long macromolecules could be stable in solution. Consequently, numerous alternative theories of the protein primary structure were proposed, e.g., the colloidal hypothesis that proteins were assemblies of small molecules, the cyclol hypothesis of Dorothy Wrinch, the diketopiperazine hypothesis of Emil Abderhalden and the pyrrol/piperidine hypothesis of Troensgard (1942). Most of these theories had difficulties in accounting for the fact that the digestion of proteins yielded peptides and amino acids. Proteins were finally shown to be macromolecules of well-defined composition (and not colloidal mixtures) by Theodor Svedberg using analytical ultracentrifugation. The possibility that some proteins are non-covalent associations of such macromolecules was shown by Gilbert Smithson Adair (by measuring the osmotic pressure of hemoglobin) and, later, by Frederic M. Richards in his studies of ribonuclease S.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in the cellular production of NAD+.
No. NMN is a smaller precursor molecule, while NAD+ is a dinucleotide cofactor used in many reactions. Enzymes called NMNAT convert NMN into NAD+ inside cells.
This question is not fully settled. Some evidence suggests NMN may be dephosphorylated to nicotinamide riboside before uptake, while other studies propose direct transport. Tissue-specific handling in humans remains an open research area.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.